Categories Earnings, Technology

What to expect when DocuSign (DOCU) reports Q4 results?

DocuSign Inc. (NASDAQ: DOCU) is slated to report fourth quarter 2020 earnings results on Thursday, March 12, after the market closes. Analysts have projected earnings of $0.05 per share which compares to earnings of $0.06 per share reported a year ago. Revenue is expected to rise 33% to $266 million.

DocuSign’s stock has gained 28% over the past one year but has dropped over 15% in the past one month alone. The stock is currently trading 19% below its 52-week high of $92.55.

The quarterly results are likely to benefit from growth in billings and an expansion in the customer base. The company has seen double-digit increases in subscription and professional services revenues and this trend can be expected to continue in the to-be-reported quarter as well.

Also read: Meet Group Q4 2019 Earnings Report

DocuSign continues to roll out new offerings which will help in expanding its portfolio and growing its customer base. This in turn will boost the topline and drive growth. The company is also investing in new technologies to improve its capabilities.  

Last month, DocuSign announced its intention to purchase contract analytics and AI technology provider Seal Software for $188 million in cash. The deal will help in integrating Seal’s technology across DocuSign’s Agreement Cloud and thus delivering greater value to clients. Updates on this transaction will be worth watching.

In the third quarter of 2020, DocuSign beat market estimates, with a 40% increase in revenues to $249.5 million and adjusted EPS of $0.11.

For the fourth quarter, the company has guided for total revenue of $263-267 million, while for the full year of 2020, revenues are expected in the range of $962-966 million.

DocuSign’s shares were down nearly 7% in afternoon hours on Wednesday.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top